Cargando…

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

OBJECTIVE: To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. METHODS: Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devinsky, Orrin, Patel, Anup D., Thiele, Elizabeth A., Wong, Matthew H., Appleton, Richard, Harden, Cynthia L., Greenwood, Sam, Morrison, Gilmour, Sommerville, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890607/ https://www.ncbi.nlm.nih.gov/pubmed/29540584 http://dx.doi.org/10.1212/WNL.0000000000005254

Ejemplares similares

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
por: Devinsky, Orrin, et al.
Publicado: (2020)

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
por: Morrison, Gilmour, et al.
Publicado: (2019)

Cannabidiol for epilepsy (Lennox-Gastaut syndrome, Dravet syndrome)
Publicado: (2020)

Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol
por: Xu, Changqing, et al.
Publicado: (2021)

Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder
por: Devinsky, Orrin, et al.
Publicado: (2021)

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial
por: Miller, Ian, et al.
Publicado: (2020)

Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea
por: Koo, Chung Mo, et al.
Publicado: (2020)

Cannabidiol improves survival and behavioural co‐morbidities of Dravet syndrome in mice
por: Patra, Pabitra Hriday, et al.
Publicado: (2020)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
por: Szaflarski, Jerzy P., et al.
Publicado: (2018)

Combined Antiseizure Efficacy of Cannabidiol and Clonazepam in a Conditional Mouse Model of Dravet Syndrome
por: Chuang, Shu-Hui, et al.
Publicado: (2021)

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
por: Taylor, Lesley, et al.
Publicado: (2019)

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
por: Tayo, Bola, et al.
Publicado: (2019)

Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
por: Silvinato, Antônio, et al.
Publicado: (2022)

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
por: Taylor, Lesley, et al.
Publicado: (2018)

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
por: Madan Cohen, Jennifer, et al.
Publicado: (2021)

Dravet Syndrome: An Overview
por: Anwar, Arsalan, et al.
Publicado: (2019)

Caregivers’ Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study
por: Marshall, Jade, et al.
Publicado: (2023)

Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome
por: Iannone, Luigi Francesco, et al.
Publicado: (2021)

Dravet syndrome
por: Incorpora, Gemma
Publicado: (2009)

Fenfluramine significantly reduces day‐to‐day seizure burden by increasing number of seizure‐free days and time between seizures in patients with Dravet syndrome: A time‐to‐event analysis
por: Sullivan, Joseph, et al.
Publicado: (2021)

Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome
por: Lattanzi, Simona, et al.
Publicado: (2021)

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects
por: Crockett, Julie, et al.
Publicado: (2020)

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
por: Arnold, Jonathon C., et al.
Publicado: (2022)

Vaccinations and Dravet Syndrome
por: Korff, Christian M.
Publicado: (2015)

Phenotypes of Dravet Syndrome
por: Garcia-Sosa, Rebecca, et al.
Publicado: (2016)

Stiripentol for Dravet syndrome
Publicado: (2020)

Inadequate Regulation Contributes to Mislabeled Online Cannabidiol Products
por: Freedman, Daniel A., et al.
Publicado: (2018)

Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial
por: McCartney, Danielle, et al.
Publicado: (2022)

On the Right Trk: Towards an Effective Treatment for Dravet Syndrome
por: Wong, Jennifer C.
Publicado: (2022)

Crouch Gait in Dravet Syndrome
por: Black, Laura, et al.
Publicado: (2016)

Anesthetic considerations in Dravet syndrome
por: Macdonald‐Laurs, Emma, et al.
Publicado: (2022)

Open the Window for the Cure of Dravet
por: Gu, Bin
Publicado: (2022)

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
por: Wu, Joyce Y., et al.
Publicado: (2022)

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study
por: Lai, Wyman W., et al.
Publicado: (2020)

Do All Roads Lead to Rome? Genes Causing Dravet Syndrome and Dravet Syndrome-Like Phenotypes
por: Ding, Jiangwei, et al.
Publicado: (2022)

Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses
por: Umpierrez, Laísa S., et al.
Publicado: (2022)

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam
por: VanLandingham, Kevan E., et al.
Publicado: (2020)

Fatal Status Epilepticus in Dravet Syndrome
por: De Liso, Paola, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n8hn25f750plbt5t4cee3ta06m